Phase II Study of Oxaliplatin, Xeloda, and cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer.

Trial Profile

Phase II Study of Oxaliplatin, Xeloda, and cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2017 Planned End Date changed from 1 Jun 2017 to 28 Jun 2018.
    • 08 Apr 2017 Planned primary completion date changed from 1 Jun 2016 to 28 Dec 2017.
    • 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top